Hello,

Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board.

Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox.

You’re just two quick steps away from completing your sign-up:

1. Make sure our emails go to your inbox

Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary

Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP

Other providers:
Reply to this message and add [email protected] to your contacts

2. Confirm your subscription

Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter.

Confirm your subscription here.

After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link.

Thanks again for subscribing—we look forward to being part of your investing journey.

Matthew Paulson
Founder and CEO, MarketBeat.

P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.

3 Reasons Analysts Love DexCom

Authored by Nathan Reiff. Article Posted: 5/5/2026.

While GLP-1 agonists have grabbed investor attention for their potential as weight loss aids, these medicines also play a crucial role in the broader effort to address type 2 diabetes. With about 40 million people in the United States suffering from diabetes and type 2 diabetes rising across multiple demographics, the core purpose of this drug class remains just as relevant as it was when these medicines first became available.

This is where medical device firms like DexCom Inc. (NASDAQ: DXCM) come into play. DexCom is not directly involved in the GLP-1 agonist space. Instead, it is known as a leader in continuous glucose monitoring (CGM) products, which are essential tools used by diabetic patients to monitor their health.

Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company (Ad)

We’ve found The Next Elon Musk… and what we believe to be the next Tesla.

It’s already racked up $26 billion in government contracts.

Peter Thiel just bet $1 Billion on it.

👉 Unlock the ticker now and get it completely free.

Even as makers of GLP-1 drugs have captured significant interest across Wall Street, DexCom is quietly building analyst support. DXCM shares currently enjoy 20 Buy ratings compared to four total Sell or Hold ratings, as well as about 40% upside.

Analyst enthusiasm may stem from three key developments: strong financial performance, a recent product launch featuring a wearable sensor, and an expansion of manufacturing capacity.

DexCom Starts 2026 With Excellent Fundamental Momentum

First, consider DexCom's financials from its latest earnings report for Q1 2026. The company beat analyst expectations for both earnings per share (EPS) and revenue. Quarterly sales came in at $1.2 billion, up 15% year-over-year (YOY), and EPS beat estimates by 9 cents. Along with these gains, both gross margin and cash generation improved. Specifically, the company boosted free cash flow and ended the quarter with about $2.4 billion in cash.

Management reaffirmed full-year revenue guidance and increased guidance for operating profit and EBITDA margin. Driving many of these performance metrics is a key update involving pharmacy benefit manager Prime Therapeutics, which will cover DexCom's CGM products for many new patients starting in summer 2026.

Success of G7 Sensor Line

Just months ago, DexCom launched its latest CGM line, G7, improving functionality, accessibility, and wear time relative to its prior offerings. The G7 15-Day CGM system is smaller and more user-friendly than DexCom's earlier products, and it features a wearable sensor that provides continuous monitoring for up to 15 days.

Launching in the final weeks of 2025, the G7 15-Day CGM has seen a strong product rollout. The company expects about 50% of its customer base to convert to the latest version by the end of 2026. With longer wear times and an improved algorithm already built into the product, DexCom is also working to further enhance the G7 CGM with software updates and other benefits.

What's more, DexCom's Stelo line of CGMs is designed for diabetic and pre-diabetic patients who do not use insulin. With additional features such as meal logging and other health tracking, it could help broaden the company's addressable market beyond diabetes patients and turn the firm into a more expansive consumer health platform, not just a wearable medical device company.

Manufacturing Expansion Boosts Margins

DexCom's rising margins are due in large part to manufacturing improvements as the company invests in capacity expansion. The significant cash reserves DexCom has accumulated are also essential, allowing the firm to meet rising demand around the world and expand its international operations.

Specifically, DexCom has highlighted improved throughput and inventory management as two of the main factors behind margin expansion last quarter. A new patch adhesive is also helping to improve sensor survivability.

DexCom shares are down about 10% year-to-date, and risks still remain for investors, including competition from major players like Medtronic PLC (NYSE: MDT) and pricing pressure as the market continues to expand. As a medical device company, DexCom is also subject to volatility tied to insurance dynamics, reimbursement trends, and changing regulatory guidelines.

Nonetheless, DexCom's strong financial growth, improving margins, latest product line, and impressive cash position — which supports aggressive expansion efforts — all point to the firm continuing to cement its position as a go-to provider of diabetes management tools. Expanding its efforts to non-insulin users also helps DexCom position itself as a broader wearable health tech company.